IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma

Qi Bai; Li Liu; Yu Xia; Jiajun Wang; Wei Xi; Yang Qu; Ying Xiong; Qilai Long; Jiejie Xu; Jianming Guo

doi:10.18632/oncotarget.17777

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma

Qi Bai, Li Liu, Yu Xia, Jiajun Wang, Wei Xi, Yang Qu, Ying Xiong, Qilai Long, Jiejie Xu _ and Jianming Guo

PDF | HTML | How to cite

Oncotarget. 2017; 8:44186-44194. https://doi.org/10.18632/oncotarget.17777

Metrics: PDF 1753 views | HTML 2264 views | ?

Abstract

Qi Bai1,*, Li Liu1,*, Yu Xia1,*, Jiajun Wang1, Wei Xi1, Yang Qu1, Ying Xiong1, Qilai Long1, Jiejie Xu2 and Jianming Guo1

1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

*These authors contributed equally to this work

Correspondence to:

Jiejie Xu, email: [email protected]

Jianming Guo, email: [email protected]

Keywords: clear cell renal cell carcinoma, IFN regulatory factor-5, nomogram, overall survival, recurrence free survival

Received: November 24, 2016 Accepted: April 25, 2017 Published: May 11, 2017

ABSTRACT

Background: IRF5 is one member of IRFs family, and is critical for host immunity and cell response. In the present study, we sought to search the clinical and prognostic value of IFR5 in patients with non-metastatic ccRCC.

Results: IRF5 proved to be an adverse independent prognostic factor for overall survival (p < 0.001) and recurrence free survival (p = 0.002). The newly built nomograms could give better prediction for overall survival and recurrence free survival in ccRCC patients.

Materials and Methods: We included 264 individuals who were diagnosed with non-metastatic clear cell renal cell carcinoma in the present study. Immunohistochemistry staining was performed on tissue microarrays to evaluate the IRF5 expression. χ² test, Fisher's exact test, t test, Kaplan-Meier method and Cox proportional hazard model were applied to evaluate the prognostic value of IRF5. Two nomograms were constructed to predict clinical outcomes for ccRCC patients after surgery.

Conclusions: IRF5 was an adverse independent prognostic factor for both overall survival and recurrence free survival in patients with non-metastatic ccRCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17777

Publication Alerts

Research Papers:

IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma

Abstract